India's NPPA slashes more drug prices

20 March 2017

As stipulated under the Indian Drugs Price Control Order (DPCO), drug pricing regulator the National Pharmaceutical Pricing Authority (NPPA) has slashed the price of cancer drugs by up to 86% since a year ago, with several more cuts in the offing, reports The Pharma Letter’s India correspondent.

Aiming to provide relief to patients, the NPPA is looking to further reduce drug prices for cardiovascular diseases, for cancer drugs, as well as for local anaesthetic agents.

Anti-inflammatory drugs and those for low and high blood pressure, amphotericin injection, antifungal medications, as well as local anesthetic medications are further set to get cheaper by 25% to 30%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK